The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

about

Targeting protein quality control pathways in breast cancer.LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

P2860

Q46087491-6E48C683-3046-4188-9610-68223A37BB6F Q53686361-E9DE00AA-539F-423A-85C9-2F29DC3714E9

P2860

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

Item

http://www.wikidata.org/entity/Q41592949

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The anti-ErbB2 antibody H2-18 ...... -overexpressing breast cancer.

@en

type

Item

label

The anti-ErbB2 antibody H2-18 ...... -overexpressing breast cancer.

@en

prefLabel

The anti-ErbB2 antibody H2-18 ...... -overexpressing breast cancer.

@en

P1476

The anti-ErbB2 antibody H2-18 ...... -overexpressing breast cancer.

@en

P2093

Beibei Liang

http://www.w3.org/2001/XMLSchema#string

Chao Wang

http://www.w3.org/2001/XMLSchema#string

Chaohua Hu

http://www.w3.org/2001/XMLSchema#string

Huafeng Wei

http://www.w3.org/2001/XMLSchema#string

Huajing Wang

http://www.w3.org/2001/XMLSchema#string

Jian Dong

http://www.w3.org/2001/XMLSchema#string

Jian Zhao

http://www.w3.org/2001/XMLSchema#string

Jie Gao

http://www.w3.org/2001/XMLSchema#string

Lingfei Wang

http://www.w3.org/2001/XMLSchema#string

Shujun Pan

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease

Unraveling the microenvironmental influences on the normal mammary gland and breast cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

P304

52877-52888

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17907

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hao Wang

Bohua Li

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28881779

http://www.w3.org/2001/XMLSchema#string

P921

overexpression

P932

5581078

http://www.w3.org/2001/XMLSchema#string

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

about

P2860

P2860

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932